JD HEALTH (06618.HK) Latest News & Headlines | Longbridge

Top 5 HK Stock Gainers/Losers (>100B) (9.9)
Top Gainers&Losers·10 hours ago
- On September 9, 2026, the Hang Seng Index fell by 0.17 % and the Hang Seng Tech Index dropped by 0.76 %. - Among major Hong Kong stocks with a market value exceeding 100 billion, Yangtze Optical Fibre and Cable surged 7.24 % with a turnover of 6.69 billion HKD. - Lenovo Group also recorded a significant increase of 6.79 % with a turnover of 3.14 billion HKD, while other firms like Fast Retailing and Sino Biopharmaceutical experienced declines of 5.52 % and 4.02 % respectively.
06869+7.24%00992+6.79%
Hong Kong Close: Hang Seng slips 0.17%; Lenovo, Weichai surge over 6%; Haidilao plunges 9%
Market Pulse·10 hours ago
- On September 9, Hong Kong stock indices closed slightly lower, with the Hang Seng Index down 0.17 % to 25274.96 points. - AI server and electric power equipment concepts strengthened, as Lenovo Group surged over 6 % due to strong AI business growth and Weichai Power gained more than 6 %. - Conversely, dining and consumer stocks plunged heavily, driven by Haidilao dropping over 9 % following a major shareholder reduction.
02338+6.45%06862-9.14%
STOCKS | JD.com Falls 2.3% As It Launches Physical AI Acceleration Plan
CoinLive·11 hours ago
JD-2.46%KJD-5.39%
JD Health falls 4% after removal from tech index
HK Stock Market Update·17 hours ago
06618-3.66%
Divergent Fundamentals in Hong Kong Equities: From Property Overhauls to Biotech Earnings
Global Report·1 day ago, 11:33 AM
- In 2026, Hong Kong stock market fundamentals exhibit significant divergence across sectors, reflecting complex economic recovery trajectories. - The real estate sector faces ongoing restructuring pressures, with Country Garden reporting a net loss of 15.616 billion RMB in mid-2026, while the biopharmaceutical sector shows rapid expansion, highlighted by Everest MediPharm achieving 1.148 billion RMB in revenue with a year-on-year growth of 157%. - Consumer goods, manufacturing, and traditional industries experience mixed performance due to rising costs and sluggish demand, prompting increased market interest in defensive assets like dividend low-volatility ETFs.
02865-1.65%03396+7.96%
Shenwan Hongyuan's Profit Surge Contrasts with JD Health's Strategy Shift Amid Index Exclusion
Global Report·1 day ago, 09:18 AM
- Shenwan Hongyuan achieved a net profit increase of 33.76 % and successfully redeemed 500 million yuan in bonds, reflecting the recovery of the financial sector. - JD Health experienced a 70 % surge in operating profit in the first quarter of 2026, though it was removed from the Tech 100 Index in September. - To counter this market adjustment, JD Health partnered with Jiuzhoutong for a 3-year cooperation exceeding 10 billion yuan to deepen its real-economy footprint.
06618-3.66%09993-2.70%
Weekly Recap | JD HEALTH +1.53%, interim report sparks margin debate
Weekly Review·Sep 5 at 05:38 AM
- JD Health's stock cumulative rose 1.53 % to close at 37.06 HKD this week, outperforming the Hang Seng Index. - The company released its 2026 interim report, sparking market discussions regarding profit sustainability and margin quality amid supply chain pressures. - Eighteen institutions maintained a consensus strong buy rating with an average target price of 68.26 HKD.
06618-3.66%
The Margin Mirage: JD Health, Commoditization, and the Value Chain Reality
Global Report·Sep 4 at 10:12 AM
- The article argues that the Hong Kong stock market is fundamentally revaluing scale versus profit quality, phasing out low-margin retail models lacking pricing power. - Evidence shows that JD Health was removed from the Tech 100 Index in September 2026 due to its heavy reliance on low-margin product sales, while Fufeng Group suffered an 80 % net profit plunge from commodity price drops. - The conclusion emphasizes that sustainable structural advantages require irreplaceable intangible assets, IP protection, and ecosystem moats rather than mere scale.
01890-1.18%06618-3.66%
Weekly Recap | JD HEALTH -1.71%, removed from HKEX Tech 100 Index
Weekly Review·Aug 29 at 04:52 AM
- JD Health's stock fell 1.71 % this week to close at 36.68 HKD, underperforming the Hang Seng Index by 1.97 percentage points. - The company was removed from the HKEX Tech 33 Index in the quarterly review, which may trigger passive capital outflows. - Despite 18 institutions giving an overall consensus strong buy rating with a target price of 68.30 HKD, analysts remain divided on the earnings recovery pace.
06618-3.66%
HKEX Tech 100 Index Quarterly Review Adds 10 Stocks Including WERIDE-W , PONY-W , INSILICO ; Removes 14 Stocks Including CHINA LIT , JD HEALTH
AASTOCKS News·Aug 28 at 09:46 AM
- HKEX announced the results of the September quarterly review for the HKEX Tech 100 Index using an optimized compilation methodology. - The index will add 10 constituent stocks including WERIDE - W, PONY - W, and INSILICO, while removing 14 stocks such as CHINA LIT and JD HEALTH. - All constituent changes will be implemented after market close on September 11 and take effect on September 14.
HKXCY-1.34%03696+4.23%
Hong Kong Stocks Close Lower: Hang Seng Dips 0.34% as Innovative Drugs & Semiconductors Buck Trend; Mixue Ice Cream Tumbles Over 8%
Market Pulse·Aug 27 at 08:19 AM
- On August 27, Hong Kong stocks closed lower collectively, with the Hang Seng Index down 0.34% to 25565.74 points and a total turnover of approximately 2335 billion HKD. - Innovative drug and semiconductor sectors bucked the trend and strengthened significantly, driven by robust earnings reports and Nvidia's strong performance. - Conversely, consumption stocks like Mixue Group plunged over 8% due to disappointing semi-annual results, while autonomous driving stocks declined amid stricter regulatory policies.
03692-3.55%06809-1.67%
Signals from Hong Kong: Divergence Deepens Across Restructuring and Recovery Plays
Global Report·Aug 25 at 11:33 AM
- Recent Hong Kong stock market movements reveal significant sector divergence ranging from regulatory restructuring to financial and consumer performance. - Futu Holdings reported strong second-quarter revenue of 7.2 billion HKD, while Liaoning Financial Holding offered 3.15 billion RMB to acquire Jinzhou Bank shares amid ongoing risk resolution. - China Hongqiao achieved a 39.2 % surge in net profit driven by aluminum prices, whereas Vanke narrowly avoided default and Evergrande Property faced severe pressure following its parent company's delisting.
02533-3.48%03288-1.34%
Earnings and Clinical Wins Fuel Hong Kong Biotech Recovery
Global Report·Aug 25 at 09:21 AM
- Driven by strong earnings and pipeline milestones, the Hong Kong stock biomedicine sector shows a significant recovery trend this year. - JD Health reported 2026 first-half total revenue of 40.888 billion RMB, with Non-IFRS operating profit surging 40.3% to 3.5 billion RMB. - Zai Lab advanced its innovative drug pipeline as VYVGART Hytrulo met its Phase III clinical trial primary endpoint and Zoci secured FDA orphan drug designation.
06618-3.66%09959+2.53%
Weekly Recap | JD HEALTH -1.18%, most brokers rate it buy
Weekly Review·Aug 22 at 04:17 AM
- JD Health accumulated a 1.18% decline this week to close at 38.66 HKD, underperforming the Hang Seng Index by 3.37 percentage points. - Despite Nomura lowering its target price due to regulatory pressures on nutritional supplements, 14 out of 18 institutions maintained a buy rating, resulting in a consensus strong buy and an average target price of 68.17 HKD. - Future performance depends on regulatory clarity regarding nutritional supplements and the stock's ability to stabilize above 38 HKD amidst broader market shifts.
06618-3.66%
Top 5 HK Stock Gainers/Losers (>100B) (8.20)
Top Gainers&Losers·Aug 20 at 08:30 AM
- On August 20, the Hang Seng Index rose 0.8% and the Hang Seng Tech Index increased by 0.39%. - Among Hong Kong stocks with a market value exceeding 100 billion, Sino Biopharmaceutical surged 12.53% and Zijin Gold International gained 11.25%. - Conversely, Kuaishou-W dropped 11.01% and Hengrui Pharma declined 9.63%.
01177-4.02%02259+2.00%